Patients, Politics, and the FDA: Who Decides What’s Enough Evidence?

Send us a text🎯 Why ListenDive into one of the most consequential debates in medicine: how should the FDA balance speed, safety, and patient need in approving new drugs and gene therapies? Dr. Bob Goldberg, joins the Doctors Lounge to unpack regulatory science, RCTs, accelerated approvals, and the controversies around muscular dystrophy treatments.👥 Co-HostsDutch Rojas – Founder, Bliksem HealthAnthony DiGiorgio, DO, MHA – Neurosurgeon, UCSF; health policy researcherAnish Koka, MD – Cardiologist, Philadelphia; healthcare policy commentatorDan Choi, MD, FAAOS – Orthopedic spine surgeon, Long Island; healthcare advocate and social media voiceSanat Dixit, MD, FACS – Neurosurgeon, Huntsville, AL; Faculty, Vanderbilt University; healthcare entrepreneur✨ Special GuestBob Goldberg, PhD – Co-Founder & Vice President, Center for Medicine in the Public Interest📌 Episode OverviewThis episode explores the tension between innovation and evidence in drug development. Dr. Goldberg shares his decades of work in FDA reform and patient-centered drug development. The discussion spans accelerated approvals, Sarepta’s muscular dystrophy drugs, RCTs vs. real-world evidence, and the risks of leaning too far toward either bureaucratic caution or patient desperation.💬 Notable Quotes“Drug development is harder than hitting a fastball Sandy Koufax would throw.” – Bob Goldberg“Randomization is a very limited tool… there are many more ways to generate meaningful evidence.” – Bob Goldberg“If we don’t have some dead ends in accelerated approvals, then we’re not doing enough of them.” – Janet Woodcock (quoted by co-hosts)“Patients don’t care about motor function endpoints—they care about breathing, dignity, and independence.” – Bob Goldberg📚 What You’ll LearnWhy RCTs are not always the gold standard in rare diseasesThe backstory of Sarepta’s muscular dystrophy approvalsHow patient-centered drug development reshapes trial endpointsThe role of politics and policy in FDA decision-makingBarriers that slow innovation, from trial costs to regulatory red tapeHow AI and adaptive trial design could accelerate safer drug development⏱ The Episode (Timestamps)00:00 – Regulatory science, biomarkers, and the challenge of precision medicine01:00 – Introduction of guest Dr. Bob Goldberg02:00 – Background: Center for Medicine in the Public Interest & FDA reform06:00 – The limits of randomization and the rise of precision endpoints10:00 – Gene therapy for muscular dystrophy: risks, deaths, and FDA holds14:00 – Critiques of Vinay Prasad and the politics of FDA appointments20:00 – Exondys 51, Sarepta, and the accelerated approval debate30:00 – Historical parallels: AIDS drug approvals and patient advocacy40:00 – Patient-centered drug development and real-world data50:00 – Trial design inefficiencies, AI, and regulatory bottlenecks57:00 – Pharma lobbying, PBMs, and the rebate system01:04:00 – Public perception, patient voice, and FDA trust01:09:00 – Closing though🔗 Connect with the Hosts: • Dutch Rojas on X • Dr. Anthony DiGiorgio on X • Dr. Anish Koka on X • Dr. Dan Choi on X • Dr. Sanat Dixit on X